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As with all drugs, fluid therapy must be regarded as context 
sensitive. If a drug is given in the wrong context to the wrong 
patient and without a proper indication, only the side-effects of 
the drug will be seen, with probable demonstrable harm. Fluids, 
as with all drugs, should only be administered in the proper 
context in which consideration is given to the pharmacological 
properties of the agent being administered, the condition for 
which the drug is being given, and the expected benefits and 
possible harm. Without clear consideration of the context, drug 
administration is negligent and harmful.
Intravenous fluids should only be administered in the context 
for which they are intended. If the context is the replenishment 
of intracellular fluid, a very different fluid composition will be 
needed compared to that used in the context in which the 
objective is the replenishment of extracellular fluid. In the 
context of plasma volume replacement, the context is again 
different, and a different fluid composition is needed.
The pathological circumstances in which fluids are administered 
thus forms the basic determinant of the context in which the 
fluids are to be administered, and ought to determine the 
composition, and dose and rate at which those fluids are to 
be administered. The current fluid debate has been seriously 
compromised by the failure of numerous authors to consider 
the context in which various fluid trials have been conducted.1,2 
The context in which recent fluid trials have been conducted can 
be divided into three patient categories: the critically ill in the 
intensive care unit, and general surgical and cardiac surgical. 
A physiologically important difference between the critically 
ill patients and the others lies in the state of the endovascular 
glycocalyx.2
The endothelial glycocalyx is a complex structure that lines 
healthy blood vessel walls. It comprises sulphated proteoglycans, 
hyaluronic acid, heparan sulphate, glycoproteins and plasma 
proteins, and forms a surface layer that binds the plasma proteins, 
creating the functional oncotic pressure gradient across the 
vascular endothelium.3 If this layer is intact, the oncotic volume 
effect of the colloids far exceeds that of the crystalloids.4
The choice of solution in context-sensitive fluid therapy 
depends on the objective of the treatment. If the intention 
is to replace free water or intracellular water, a low-sodium, 
dextrose-containing solution is appropriate, with the volume 
administered being determined by a clinical judgement of the 
degree of dehydration. If the objective is to replace extracellular 
fluid, the appropriate solution is a crystalloid with an electrolyte 
composition resembling extracellular fluid. The volume of such 
fluid is again context sensitive and should be calculated from any 
estimated deficit in the extracellular space, together with ongoing 
requirements for fluid replacement. Such a solution should not 
impose a metabolic load in terms of its ion composition, and 
should not induce major acid-base disturbances. Solutions 
such as “normal” saline consistently induce metabolic acidosis,5 
and may result in an increased incidence of complications,6 
and possibly increased mortality.7  However, the consistent 
demonstration that crystalloid overload is harmful is the clearest 
evidence that we have in the field of fluid therapy.8-10
In the context of pure hypovolaemia, large volumes of crystalloid 
solutions are required to replace lost blood volume.11 In the 
context of acute intravascular hypovolaemia, logic dictates that 
the most appropriate fluid to be administered be one that should 
most resemble the lost volume, such as a blood, plasma or a colloid 
solution, to effectively re-expand the vascular compartment. 
It has been clearly demonstrated in animal models, which lack 
the unpredictable variability of the clinical situation, that colloid 
solutions are 3-4 times as effective as crystalloid in the face of 
hypovolaemic shock secondary to blood loss.11 The synthetic 
colloids were developed as a possible solution to the combined 
problems of cost, lack of availability and risk associated with 
human-derived colloid solutions, such as albumin. Critical care 
studies performed on patients already stabilised in the intensive 
care unit were performed in an inappropriate context in which 
there was no clear evidence for hypovolaemia, no appropriate 
dosage regime and no clear protocol regarding important 
secondary end-points, such as the use of renal replacement 
therapy.12,13 In the latter study, the context was entirely one of 
sepsis, in which prior haemodynamic stabilisation had already 
been achieved, in many cases with colloid.
Current evidence supports the use of colloid solutions, such as 
modern hydroxyethyl starch, in the context of perioperative 
and trauma medicine, when acute plasma volume changes 
occur, if plasma volume expansion is appropriate and when 
haemodynamic stabilisation is undertaken in the acute phase.14-16
The question of the appropriate volumes of fluid to be 
administered in the perioperative period remains contentious. 
It has been suggested that the most logical approach to 
perioperative fluid therapy should be to target “zero balance” 
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in which the patient’s weight from the first postoperative day is 
within a 2 kg range of the preoperative value.17 A recent review 
offers reasonable guidelines. Crystalloid should be administered, 
and guided by the concept of “zero balance”, to patients with mild 
to moderate intercurrent disease undergoing moderate surgery. 
When the underlying disease state of the patient is more serious 
or the surgery more advanced, a mix of crystalloid and colloid 
fluid therapy is recommended, preferably guided by some form 
of goal-directed fluid therapy.18
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